Germline mutagenicity of molnupiravir and its active form, β-d-N4-hydroxycytidine, in Caenorhabditis elegans evaluated using whole-genome sequencing
Authors:
- 22 May 2025
- journal article
- Published by Elsevier in Toxicology Letters
- Vol. 409, 138-144
Abstract
No abstract availableKeywords
Funding Information
- U.S. Food and Drug Administration
- U.S. Department of Energy
- Oak Ridge Institute for Science and Education
This publication has 45 references indexed in Scilit:
- Caenorhabditis Elegans as a Model for Environmental EpigeneticsCurrent Environmental Health Reports, 2025
- A path from synthesis to emergency use authorization of molnupiravir as a COVID-19 therapyBioorganic Chemistry, 2024
- Evaluation of mutagenic susceptibility of different stages in germ cell development of Caenorhabditis elegans using whole genome sequencingArchives of Toxicology, 2023
- Evaluation of the mutagenic effects of Molnupiravir and N4‐hydroxycytidine in bacterial and mammalian cells by HiFi sequencingEnvironmental and Molecular Mutagenesis, 2022
- Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19Current Opinion in Virology, 2021
- Bacterial Metabolism Affects the C. elegans Response to Cancer ChemotherapeuticsCell, 2017
- The Application of CRISPR-Cas9 Genome Editing in Caenorhabditis elegansJournal of Genetics and Genomics, 2015
- Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegansNeuromuscular Disorders, 2004
- Large-scale mutational analysis of EMS-induced mutation in the lacI gene of Escherichia coliMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1993
- Mutagenic action of N4-hydroxycytidine on Escherichia coli B cyt−Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1973